latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/merit-medical-s-stent-graft-gets-2-more-us-fda-breakthrough-device-tags-57925147 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merit Medical's stent graft gets 2 more US FDA breakthrough-device tags

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Merit Medical's stent graft gets 2 more US FDA breakthrough-device tags

Merit Medical Systems Inc. received two more breakthrough-device designations from the U.S. Food and Drug Administration for its Wrapsody endovascular stent graft system.

The South Jordan, Utah-based medical-device manufacturer is developing Wrapsody for use in dialysis patients to treat stenosis, or narrowing, within the central veins of the outflow circuit of an abnormal connection or passageway between an artery and a vein up to the superior vena cava, a venous trunk that returns deoxygenated blood from the systemic circulation to the right atrium of the heart.

The new designations cover the treatment of patients with an arteriovenous fistula, an abnormal connection in a vein and an artery, within the peripheral veins in the arm, as well as patients with an arteriovenous graft — a looped plastic tube that connects an artery to a vein — in the thoracic central veins.

Thoracic central veins include segments of the internal jugular vein, subclavian veins, brachiocephalic veins and the superior vena cava.

The FDA granted the Wrapsody endovascular stent-graft system the breakthrough-device designation in November 2019 to treat a condition in certain dialysis patients. The device is not available for sale.